STOCK TITAN

Bellus Health Inc - BLU STOCK NEWS

Welcome to our dedicated news page for Bellus Health (Ticker: BLU), a resource for investors and traders seeking the latest updates and insights on Bellus Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bellus Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bellus Health's position in the market.

Rhea-AI Summary
BELLUS Health Inc. announces positive outcome of shareholder vote on acquisition by GSK
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
none
-
Rhea-AI Summary
BELLUS Health Inc. announces special meeting for shareholders to consider and adopt a special resolution approving the acquisition of the company by GSK for $14.75 per share. The meeting will be held on June 16, 2023, and shareholders of record as of May 15, 2023, will be eligible to participate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
-
Rhea-AI Summary
BELLUS Health Inc. has announced an agreement to be acquired by GSK for US$14.75 per share of common stock in cash, representing a premium of approximately 103%. The transaction is expected to close in Q3 2023. BELLUS Health is actively advancing its CALM Phase 3 clinical program for camlipixant (BLU-5937) in refractory chronic cough, with topline results expected in the second half of 2024 and 2025. The company is also pursuing the development of its P2X3 receptor pipeline. BELLUS Health reported positive results from its Phase 1 clinical trial for an Extended-Release formulation of camlipixant. The company will be presenting at the upcoming American Thoracic Society 2023 International Conference. Financially, BELLUS Health had available cash, cash equivalents, and short-term investments totaling US$313.0 million as of March 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
98.9%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
Bellus Health Inc

Nasdaq:BLU

BLU Rankings

BLU Stock Data

1.87B
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Laval

About BLU

bellus health is a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need. its lead project is blu-5937, a drug candidate for the treatment of chronic cough. bellus health also has economic interests in other partnered drug development projects. blu-5937 is a potent, highly selective, orally bioavailable small molecule antagonist of the p2x3 receptor, a clinically validated target for chronic cough. blu-5937 is a promising best-in-class drug candidate that has the potential to help millions of chronic cough patients who do not respond to current therapies. rights to blu-5937 were obtained under a license agreement with the neomed institute in february 2017. chronic cough is a cough that lasts more than eight weeks and is associated with significant adverse social, psychosocial and physical effects on quality of life. it is estimated that, in the united states alone, more than 2.7 million patients suffer from chronic cough that is